AidyWinter 2024Active☆Watch⊞Compare

Aidy is one of 233 Biotech companies tracked from San Francisco, CA, USA, on record since 2024. By capital raised it ranks mid-pack (ahead of 67% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst”

Mobile app helping people better manage chronic health conditions

Aidy is a mobile app that helps people live fuller lives with chronic health conditions, beginning with Inflammatory Bowel Disease (Crohn’s Disease and Ulcerative Colitis). Our app lets users easily log their symptoms, diet, and treatments, then uses clinical indices to track disease severity and trends over time. Aidy excels at identifying patterns between diet, treatment adherence, and symptoms, giving our users a much more comprehensive and up-to-date picture of their condition to supplement clinician care. Previously in our careers, both Max and Peter worked in health in different capacities. At the Rockefeller Foundation and the United States Senate, Max worked in public health policy and COVID-19 response, while Peter worked as an ML researcher for a number of biotech companies. After a lengthy “pivot hell” we decided to finally listen to a friend with IBD who insisted that there weren’t any decent apps to help people live with the disease. Pretty quickly, we discovered how LLMs and regular structured questionnaire responses could provide a level of patient empowerment not possible before for chronic diseases. From there, Aidy was (re)born!

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

No round amounts on record to chart.

No staged rounds to sequence.

Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Benchmarked against 233 companies in Biotech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 67% of sector peers (real $). Modeled value above 67% of peers (estimate).

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Aidy is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where Aidy sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at Aidy, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.